Similar articles

• An HIV/AIDS vaccine: where do we go from here?

  Bernstein A. Bernstein A. Trends Microbiol. 2008 Dec;16(12):553-4. doi: 10.1016/j.tim.2008.08.009. Epub 2008 Oct 27. Trends Microbiol. 2008. PMID: 18964019 No abstract available.
• Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.

  Chesney MA, Lurie P, Coates TJ. Chesney MA, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):30-5. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7712232 Review. No abstract available.
• The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.

  MacQueen KM, Buchbinder S, Douglas JM, Judson FN, McKirnan DJ, Bartholow B. MacQueen KM, et al. AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S261-4. AIDS Res Hum Retroviruses. 1994. PMID: 7865314 No abstract available.
• The challenges of an HIV vaccine enterprise.

  Wolf H. Wolf H. Science. 2004 Feb 27;303(5662):1294-7; author reply 1294-7. Science. 2004. PMID: 14991961 No abstract available.
• A safe, effective and affordable HIV vaccine--an urgent global need.

  Joseph J, Etcheverry F, Alcami J, María GJ. Joseph J, et al. AIDS Rev. 2005 Jul-Sep;7(3):131-8. AIDS Rev. 2005. PMID: 16302460 Review.